A new study indicated that treating adults hospitalised with COVID-19 with remdesivir plus a highly concentrated solution of antibodies that neutralise SARS-CoV-2 is no more effective than remdesivir alone. The research was published in 'The Lancet Journal.'
The trial, termed Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC, was sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health. The experiment was carried out by the International Network for Strategic Initiatives in Global HIV Trials, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID). The trial was directed by Mark Polizzotto, M.D., PhD, head of the Clinical Hub for Interventional Research at The Australian National University's College of Health and Medicine in Canberra.
Anti-coronavirus hyperimmune intravenous immunoglobulin, or hIVIG, was the antibody solution used in the ITAC trial. Antibodies in anti-coronavirus hIVIG were obtained from the plasma, or liquid portion of blood, donated by healthy patients who had recovered from COVID-19. These antibodies were purified and concentrated to the point where anti-coronavirus hIVIG contained several times the amount of SARS-CoV-2 neutralising antibodies detected in the plasma of persons who had recovered from COVID-19.